Progressionfree survival
-
Glioblastoma (GBM) is the most malignant primary tumor in the brain, with poor prognosis and limited effective therapies. Although Bevacizumab (BEV) has shown promise in extending progressionfree survival (PFS) treating GBM, there is no evidence for its ability to prolong overall survival (OS)
23p visharma 20-10-2023 5 2 Download
-
Clinical studies have shown that first-line use of anti-angiogenetic therapy can prolong progressionfree survival but little progress has been made in extending the overall survival of the patients. We explored the role of ELK3 in glioma angiogenesis to improve and design more efficacious therapies.
17p vioracle 29-09-2023 4 2 Download
-
Inhibitors of Poly (ADP-Ribose) Polymerases (PARP) provide clinical benefit to patients with breast and ovarian cancers, by compromising the DNA repair activity of cancer cells. Although these agents extend progressionfree survival in many patients, responses can be short lived with many patients ultimately progressing.
14p vioracle 29-09-2023 4 2 Download
-
Although chemotherapy for metastatic colorectal cancer (mCRC) has improved, the standard chemotherapy regimens for patients with RAS wild-type mCRC remain debated. This study aimed to compare S-1 and oxaliplatin (SOX) + bevacizumab (B-mab) with SOX + cetuximab (C-mab) in patients with previously untreated recurrent advanced CRC with wild-type KRAS.
10p vimahuateng 26-11-2021 4 0 Download
-
Lanreotide depot/autogel antitumor activity in intestinal/pancreatic neuroendocrine tumors (NETs) was demonstrated in the phase-3 CLARINET study (NCT00353496), based on significantly prolonged progressionfree survival (PFS) versus placebo.
9p viputrajaya2711 22-06-2020 6 0 Download